Related Experiment Video
Updated: Jun 20, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
[New molecular approaches in dermatofibrosarcoma protuberans].
1Service de dermatologie et vénéréologie, Département de médecine génétique et de laboratoire, HUG, Geneve. gkaya@hcuge.ch
Revue Medicale Suisse
|August 22, 2009
Summary
Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Imatinib mesylate shows promise for treating unresectable or metastatic DFSP, potentially enabling surgical removal.
Area of Science:
- Oncology
- Dermatology
- Genetics
Context:
- Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade skin malignancy.
- Metastases are infrequent, but local recurrence can be challenging.
- Over 90% of DFSP cases involve a COL1A1/PDGFB gene translocation.
Purpose:
- To review the management of Dermatofibrosarcoma protuberans.
- To highlight the role of imatinib mesylate in treating advanced DFSP.
- To discuss surgical and medical treatment strategies.
Summary:
- Surgical excision (wide local excision or Mohs surgery) is the primary treatment for DFSP.
- Imatinib mesylate targets platelet-derived growth factor receptors (PDGFR).
- This targeted therapy demonstrates high clinical response rates in unresectable or metastatic DFSP, sometimes facilitating subsequent surgery.
Impact:
- Imatinib mesylate offers a new therapeutic option for advanced DFSP.
- This approach may improve outcomes for patients with unresectable or metastatic disease.
- It expands treatment possibilities beyond traditional surgery.
